 |
|
|
Alan M. Krensky, M.D.
Email:
Profile: http://med.stanford.edu/profiles/Alan_Krensky/
Alternate Contact: Academic Appointments
Appointment
Organization
Professor
Member
Member
|
Curriculum Vitae PDF
Honors & Awards
Title
Organization
Date(s)
Young Investigator Award
Society for Pediatric Research
1985
Young Investigator Award
American Society of Nephrology/American Heart Association
1990
Joseph A. Shankman Award
National Kidney Foundation of Massachusetts
1983
Young Investigator Award
American Society for Histocompatibility and Immunogenetics
1985
Award for Excellence in Pediatric Research
American Academy of Pediatrics
1993
10 honors and awards: view full list
Administrative Appointments
Title
Organization
Start Year
End Year
Associate Dean
Children's Health Initiative
1999
-
Associate Chair
Stanford University School of Medicine - Pediatrics
1999
-
Shelagh Galligan Professor
Stanford University
1995
-
Chief
Division of Immunology and Transplantation Biology - Pedaitrics
1995
-
Professional Education
Degree
Awarding Institution
Field of Study
Year of Graduation
B.A.
University of Pennsylvania
Animal Behavior
1973
M.D.
University of Pennsylvania
Medicine
1977
Research Interests
Research in this laboratory focuses on using knowledge about the basic mechanisms of T lymphocyte biology in order to design novel immunotherapies for use in infectious diseases, transplantation, cancer, and autoimmune diseases. The techniques of cellular immunology, protein chemistry, and molecular biology are used in the following four projects:
1) Immunosuppressive efects of HLA derived peptides. Synthetic peptides corresponding to linear sequences of HLA molecules inhibit T lymphocyte function both in vitro and in vivo. Current studies in the laboratory focus on the mechanism of action of the peptides in signal transduction and transcriptional regulation and identification and characterization of the receptor(s) for peptide. The effect of these peptides in murine models of transplantation, diabetes mellitus, and graft versus host disease is being investigated.
2) Function and transcriptional regulation of expression of the chemokine RANTES. RANTES is a chemoattractant cytokine (chemokine) and HIV suppressor factor first identified in this laboratory. Ongoing studies involve the characterization of novel transcription factors expressed three to five days after T cell activation which are responsible for regulating the RANTES expression in T lymphocytes.
3) The novel cytolyic molecule granulysin. We identified granulysin as a T cell specific gene using subtractive hybridization. It is expressed in CTL and NK cells and kills microbes and tumor cells. Studies in the laboratory are focused on understanding the mechanism of action of granulysin in inducing apoptosis and its target specificity.
4) Role of chemokine lymphotactin in immunologic tolerance.
1) Immunosuppressive efects of HLA derived peptides. Synthetic peptides corresponding to linear sequences of HLA molecules inhibit T lymphocyte function both in vitro and in vivo. Current studies in the laboratory focus on the mechanism of action of the peptides in signal transduction and transcriptional regulation and identification and characterization of the receptor(s) for peptide. The effect of these peptides in murine models of transplantation, diabetes mellitus, and graft versus host disease is being investigated.
2) Function and transcriptional regulation of expression of the chemokine RANTES. RANTES is a chemoattractant cytokine (chemokine) and HIV suppressor factor first identified in this laboratory. Ongoing studies involve the characterization of novel transcription factors expressed three to five days after T cell activation which are responsible for regulating the RANTES expression in T lymphocytes.
3) The novel cytolyic molecule granulysin. We identified granulysin as a T cell specific gene using subtractive hybridization. It is expressed in CTL and NK cells and kills microbes and tumor cells. Studies in the laboratory are focused on understanding the mechanism of action of granulysin in inducing apoptosis and its target specificity.
4) Role of chemokine lymphotactin in immunologic tolerance.
Publications
- Huang LP, Lyu SC, Clayberger C, Krensky AM "Granulysin-mediated tumor rejection in transgenic mice." J Immunol 2007; 178: 1: 77-84 More »
- Krensky AM, Ahn YT "Mechanisms of disease: regulation of RANTES (CCL5) in renal disease." Nat Clin Pract Nephrol 2007; 3: 3: 164-70 More »
- Wu B, Huang C, Kato-Maeda M, Hopewell PC, Daley CL, Krensky AM, Clayberger C "Messenger RNA Expression of IL-8, FOXP3, and IL-12beta Differentiates Latent Tuberculosis Infection from Disease." J Immunol 2007; 178: 6: 3688-94 More »
- Cohen AC, Nadeau KC, Tu W, Hwa V, Dionis K, Bezrodnik L, Teper A, Gaillard M, Heinrich J, Krensky AM, Rosenfeld RG, Lewis DB "Cutting Edge: Decreased Accumulation and Regulatory Function of CD4+CD25high T Cells in Human STAT5b Deficiency." J Immunol 2006; 177: 5: 2770-4 More »
- Ahn YT, Huang B, McPherson L, Clayberger C, Krensky AM "Dynamic Interplay of Transcriptional Machinery and Chromatin Regulates "Late" Expression of the Chemokine RANTES in T Lymphocytes." Mol Cell Biol 2006; More »
189 publications: view full list
